Markers of endothelial activation and damage in haematological patients in relation to efficacy of transfusion support: a pilot study.

Completed

• Conditions: blood diseases; Haematological diseases; 10018849

• Registration Number: NL-OMON31260
• Lead Sponsor: HagaZiekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

1. Age > or <= 18 years
2. Hemato-oncologic diagnosis, expected to receive > 2 platelet transfusions
3. patients with sickle cell disease
4. informed consent

Exclusion Criteria

1. Active cardiovascular disease
2. Recent thrombotic event
3. The usage of Ascal

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Clinical endpoints:<br /><br><br /><br>For the hemato-oncological patients:<br /><br>- bleeding complications<br /><br>- transfusion efficacy<br /><br><br /><br>For the SCD patients<br /><br>- occurence/existence of organ damage<br /><br><br /><br>Laboratory determination of:<br /><br><br /><br>P-selectin, activated leukocytes, micro-particles, integrines and cytokines by<br /><br>flowcytometry;<br /><br>Hyaluronic acid, vWF and its propeptide with ELISA technique;<br /><br>and platelet aggregation assays.<br /><br>Gene expression.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>